{
    "clinical_study": {
        "@rank": "62186", 
        "acronym": "FINESSE", 
        "arm_group": {
            "arm_group_label": "lucitanib", 
            "arm_group_type": "Experimental", 
            "description": "Hard gelatine capsules of 5 and 10 mg, 15 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent"
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the objective response rate (ORR) of single agent\n      lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified\n      with 11q amplification, or FGFR1-non amplified without 11q amplification."
        }, 
        "brief_title": "A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed breast adenocarcinoma.\n\n          -  Presence of an accessible metastatic lesion for biopsy or at least one archived\n             metastatic tumour sample.\n\n          -  Prior first-line hormonal therapy in the metastatic setting.\n\n          -  Demonstrated progression of disease by radiological or clinical assessment.\n\n          -  Female patient, aged \u226518 years old.\n\n          -  Estimated life expectancy >3 months.\n\n          -  Normal Left ventricular function\n\n          -  Adequate haematological, hepatic and renal functions.\n\n          -  For women with childbearing potential, a negative pregnancy test prior to initiation\n             of the study drug and willingness to use an effective contraception.\n\n          -  Ability to swallow oral capsules.\n\n        Exclusion Criteria:\n\n          -  More than two lines of chemotherapy and two lines of hormonal therapy with or without\n             targeted therapy in the metastatic setting.\n\n          -  Previous treatment with bevacizumab within 3 months of first dose of Investigational\n             Medicinal Product.\n\n          -  Active central nervous system metastases, cerebral oedema, and/or progressive growth.\n\n          -  Patients with impaired cardiac function.\n\n          -  Patients with history of thrombotic disorders or hereditary risk factors of\n             thromboembolic events\n\n          -  Serum potassium level below Lower Limit of Normal\n\n          -  Uncontrolled hypothyroidism.\n\n          -  Pregnant or breastfeeding women."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "123", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02053636", 
            "org_study_id": "CL2-80881-001", 
            "secondary_id": [
                "2013-000288-10", 
                "BIG 2-13"
            ]
        }, 
        "intervention": {
            "arm_group_label": "lucitanib", 
            "intervention_name": "lucitanib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Estrogens"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charleroi", 
                        "country": "Belgium", 
                        "zip": "6000"
                    }, 
                    "name": "Grand H\u00f4pital de Charleroi"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Namur", 
                        "country": "Belgium", 
                        "zip": "5000"
                    }, 
                    "name": "Clinique Sainte Elisabeth"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Cancer Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Institut Gustave Roussy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20141"
                    }, 
                    "name": "Istituto Europeo di Oncologia"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20133"
                    }, 
                    "name": "Istituto Nazionale dei Tumori"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Hospital Universitario Vall d'Hebr\u00f3n"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "Hospital Universitario Ramon y Cajal"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW3 6JJ"
                    }, 
                    "name": "Royal Marsden Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Canada", 
                "France", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer", 
        "overall_contact": {
            "email": "clinicaltrials@servier.com", 
            "last_name": "IRIS"
        }, 
        "overall_official": [
            {
                "affiliation": "Institut Gustave Roussy, France", 
                "last_name": "Fabrice Andr\u00e9, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hospital Universitario Vall d'Hebr\u00f3n, Spain", 
                "last_name": "Javier Cortes, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
                "Canada: Health Canada", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Hungary: National Institute of Pharmacy", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Spanish Agency of Medicines", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tumor evaluation every 8 weeks throughout the study", 
            "measure": "Objective response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "Every 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02053636"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Servier", 
        "sponsors": {
            "collaborator": {
                "agency": "Breast International Group", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Servier", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}